Perspective · 30 Oct 2024
Conference abstractPublished 14 Sep 2015
Update on Diabetes management
University of Florida, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Large clinical diabetes trials have demonstrated beneficial effects of lowering hemoglobin A1C on microvascular complications. Lessons from these trials revealed that sustained intensification of medical therapy is difficult and pointed towards the progressive loss of beta cell mass over time. In the light of these results, nine new classes of drugs have been introduced over the last decade. In spite of this, the newer drugs were less potent in their efficacy to lower hemoglobin A1C than insulin therapy. Furthermore, there are yet no clinical data to demonstrate their ability to preserve beta cell function in humans. Besides that, serious adverse events were noted with the newer agents. Given all that, it important to lower hemoglobin A1C, then again the way to get there is as important learning what and when to add on therapies.
Subjects
Diabetes & EndocrinologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Short communication · 21 Apr 2022
Neonatal Diabetes Mellitus: Diagnosis and Management Update
Other · 7 Jul 2016
Update on diagnosis, pathogenesis and management of ketosis-prone Type 2 diabetes mellitus
Conference abstract · 2015
Update on Diabetes Management
Conference abstract · 2014
Update on diabetes management: Learn the update on glucose lowering agents
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectDiabetes & Endocrinology
- BylineArticles whose byline prints “Mae Sheikh-Ali”
